Pacira Stock Story


USD 57.08  0.82  1.46%   

In general, we focus on analyzing Pacira (NASDAQ:PCRX) price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Pacira Pharm daily price indicators and compare them against related drivers. My story will break down Pacira Pharm. We will look into a few reasons why it is still possible for the company to generate above-average margins and positive cash flow.
Published over a week ago
View all stories for Pacira Pharm | View All Stories

Is Pacira Pharm (NASDAQ:PCRX) losing trust from investors?

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Pacira Pharm has an asset utilization ratio of 139.66 percent. This suggests that the company is making $1.4 for each dollar of assets. An increasing asset utilization means that Pacira Pharm is more efficient with each dollar of assets it utilizes for everyday operations.
About 118.0% of the company shares are owned by institutional investors. The book value of Pacira Pharm was at this time reported as 16.14. Pacira Pharm has Price/Earnings To Growth (PEG) ratio of 0.63. The entity had not issued any dividends in recent years.
The successful prediction of Pacira Pharm stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Pacira Pharm, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Pacira Pharm based on Pacira Pharm hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Pacira Pharm's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Pacira Pharm's related companies.

Use Technical Analysis to project Pacira expected Price

Pacira Pharm technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Pacira Pharm technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Pacira Pharm trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Pacira Pharm, but it might be worth checking our own buy vs. sell analysis

Sale by Slonin Jonathan of 308 shares of Pacira Pharm

Legal trades by Pacira Pharm insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Pacira insider trading alert for sale of common stock by Slonin Jonathan, Chief Clinical Officer, on 5th of August 2022. This event was filed by Pacira Biosciences Inc with SEC on 2022-08-05. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

This firm reported the previous year's revenue of 541.53 M. Net Income was 41.98 M with profit before overhead, payroll, taxes, and interest of 345.73 M.

Deferred Revenue Breakdown

Pacira Pharm Deferred Revenue yearly trend continues to be fairly stable with very little volatility. Deferred Revenue is likely to outpace its year average in 2022. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Pacira Pharm Deferred Revenue is fairly stable at the moment as compared to the past year. Pacira Pharm reported Deferred Revenue of 91,800 in 2021
20124.69 Million
20134.22 Million
201410.93 Million
20159.51 Million

Pacira may start a relapse in September

Coefficient Of Variation just dropped to -660.28, may suggest upcoming price decrease. Pacira Pharm exhibits very low volatility with skewness of -0.19 and kurtosis of -0.05. However, we advise investors to further study Pacira Pharm technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Pacira Pharm's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Pacira Pharm's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Pacira Pharm Implied Volatility

Pacira Pharm's implied volatility exposes the market's sentiment of Pacira Pharm stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Pacira Pharm's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Pacira Pharm stock will not fluctuate a lot when Pacira Pharm's options are near their expiration.

Our Conclusion on Pacira Pharm

While few other entities in the drug manufacturers—specialty & generic industry are either recovering or due for a correction, Pacira Pharm may not be performing as strong as the other in terms of long-term growth potentials. With a relatively neutral outlook on the current economy, it is better to hold off any trading of Pacira as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Pacira Pharm.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Pacira Pharm. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to